News

The PDUFA date is set for early June, and if approved, it would be the first and only single dose immunization for infants regardless of weight designed to protect them for the duration of their first RSV season.

Joseph Zackular, PhD suggests that mRNA vaccines and monoclonal antibodies could offer more effective treatments for recurrent C difficile infections

Joseph Zackular, PhD, shares insights on his team’s mRNA vaccine research for C difficile, highlighting progress in animal models and future plans for human trials.

Vedanta Biosciences offered further insights on its completed phase 2 trial for its novel therapeutic, VE303.

Health officials are investigating an outbreak called "Dinga Dinga," which causes fever and uncontrollable shaking.

In a study evaluating bulevirtide as monotherapy, investigators found the antiviral to be safe and tolerable following nearly a year of treatment.

This week, evolving COVID-19 inpatient care protocols with ECMO and remdesivir, FDA breakthrough designation for a rapid sepsis test, E coli outbreak linked to iceberg and romaine lettuce, and more.

The development of CRMA-1001, a potential functional cure for chronic hepatitis B and D, is set to enter clinical trials in 2025.

Study finds optimal timing of annual COVID-19 booster depends on regional transmission patterns and if/when breakthrough infection has occurred.

In this week's episode, the panel discusses therapies and care involving inpatients, including mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and remdesivir.

Sexual transmission was confirmed for nine of the 22 viruses studied, including Ebola, Zika, and mpox, making it a key factor in ongoing disease spread.

Jeanne Marrazzo, MD, MPH, director of NIAID, discusses the mutation changes needed to make human-to-human transmission easier as well as infection prevention strategies.

Alba Azola, MD discusses the challenges of diagnosing and managing Long COVID and its overlap with ME/CFS, emphasizing the need for individualized care and ongoing research.

The federal agency stated there were cases of RSV lower respiratory tract infection (LRTI) post-immunization for 2 of the company’s vaccines, mRNA-1345 and mRNA-1365.

Navigating the long road of Long COVID involves more than recovering from an infection; it requires specialized, multifaceted care to address ongoing and often invisible neurological symptoms.

The ongoing outbreak in the Democratic Republic of Congo is affecting mostly very young children, and has investigators searching for answers.

Interim findings from the STOMP trial reveal that tecovirimat does not significantly accelerate lesion resolution or reduce pain in mild to moderate mpox cases.

Study found that VRE colonization is linked to higher mortality, increased need for mechanical ventilation, and renal replacement therapy, while MRSA and C diff colonization showed less impact.

The MeMed Severity test can determine results within 15 minutes through a blood test and aims to offer treatment guidance with machine learning.

If confirmed by the CDC, these cases would increase the national total of human infections to 60, with 58 already reported in various states.

Focused prevention policies and support systems have shown to reduce HCV prevalence in at-risk groups. Addressing factors like IDU, lack of income, and alcohol misuse through targeted education and interventions is essential to mitigate HCV infection rates locally and globally.

Hospitalization rates for RSV in children under five are comparable to pre-pandemic levels, with the highest rates observed in infants aged 0-2 months.

A small phase 2 study evaluated Debiopharm’s investigational antibiotic, afabicin, including its clinical response rate and safety profile of 2-3 weeks of treatment for staphylococcal bone and joint infections (BJI).

A multistate outbreak of E coli O157:H7 infections has been served at catering events, restaurants, and schools.

With some young people still feeling the lingering effects of Long COVID years later, new data shows the value of COVID-19 vaccination to prevent the condition altogether.

This week, a Mayo Clinic study found that removing C diff from gastrointestinal pathogen panels reduced unnecessary treatments, a Salmonella outbreak was linked to cucumbers, and a hepatitis C therapy achieved a 98% sustained virologic response in non-cirrhotic patients, among other developments.

Milad Zandi, PhD, on rising temperatures and the spread of mosquito-borne diseases like dengue, Zika, and chikungunya, increasing the risk of outbreaks in tropical and temperate regions.

Study finds antibiotic selection generally follows CAP guidelines but identifies determinants of frequently longer treatment durations.